Abstract
A combined supplement of magnesium oxide (300 mg/day) and pyridoxine·HCl (10 mg/day) was given p.o. to 16 recurrent calcium oxalate (CaOx) stone formers, and its therapeutic efficacy was biochemically evaluated by measuring various parameters of blood (Na, K, Mg, urea, creatinine, calcium, phosphate, uric acid, alanine transaminase, aspartate transaminase and alkaline phosphatase) and urine (volume, pH, creatinine, Na, K, Mg, uric acid, calcium, phosphate, oxalate and citrate) at 0, 30, 60, 90 and 120 days of treatment. Serum Mg significantly (P<0.01) increased after 30 days of treatment and remained constant thereafter while other blood parameters were unaltered. Combined treatment led to a significant increase in the urinary excretion of Mg and citrate over pretreatment values while oxalate excretion showed a gradual and significant decline during the therapy. The results confirmed the efficacy of MgO-pyridoxine supplementation in terms of changes in urinary excretion of lithogenic and inhibitory components, leading to a significant (P<0.01) decrease in CaOx risk index from 0.09±0.04 at 0 day to 0.05±0.02 after 120 days of treatment.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Ahlstrand C, Tiselius HG (1984) Biochemical effects in patients with calcium oxalate stone disease during combined treatment with bendroflumethiazide and MgO. Br J Urol 56:125–130
Backman U, Danielson BG, Fellstrom B, Johansson G, Ljunghall S, Wikstrom B (1979) Biochemical and clinical effects of prophylactic treatment of renal calcium stones with magnesium hydroxide. Scand J Urol Nephrol [Suppl]51
Berg W, Bother C, Pirlich W, Janitzky V (1986) Influence of magnesium on the absorption and excretion of calcium and oxalate ions. Eur Urol 12:274–282
Danpure CJ (1991) Molecular and clinical heterogeneity in primary hyperoxaluria type I. Am J Kidney Dis 17:366–369
Fetner CD, Barilla DE, Townsend J, Pak CYC (1978) Effects of MgO on crystallization of calcium salts in urine in patients with recurrent nephrolithiasis. J Urol 120:399–408
Fiske CH, Subbarow Y (1925) The colorimetric determination of phosphorus. J Biol Chem 66:375–400
Gershoff SN (1964) Vitamin B6 and oxalate metabolism. Vitam Horm 22:581–589
Gibbs DA, Watts RWE (1970) The action of pyridoxine in primary hyperoxaluria. Clin Sci 38:277–286
Harrison AR, Kasidas GP, Rose GA (1981) Hyperoxaluria and recurrent stome formation apparently cured by short courses of pyridoxine. Br Med J 282:2097–2098
Henry RJ (1967) Determination of uric acid by reaction with alkaline phosphotungstate. In: Henry RJ (ed) Clinical chemistry: principles and techniques. Harper and Row, New York, pp 278–283
Hodgkinson A (1974) Relations between oxalic acid, calcium, magnesium and creatinine excretion in normal men and male patients with calcium oxalate kidney stones. Clin Sci Mol Med 46:357–367
Hodgkinson A, Williams A (1972) An improved colorimetric procedure for urine oxalate. Clin Chim Acta 36:127–132
Lindberg J, Harvey J, Pak CYC (1990) Effect of magnesium citrate and MgO on the crystallization of calcium salts in urine: changes produced by food — Mg interaction. J Urol 143:248–251
Melnick I, Lands RR, Hoffman AA, Burch JP (1971) Magnesium therapy for recurring calcium oxalate urinary calculi. J Urol 105:119–123
Menon M, Koul H (1992) Clinical review: calcium oxalate urolithiasis. J Clin Endocrinol Metab 74:703–707
Moore CA, Bunce GE (1964) Reduction in frequency of renal calculus formation by oral Mg administration. Invest Urol 2:7–13
Murthy MSR, Farooqui S, Talwar HS, Thind SK, Nath R, Rajendran L, Bapna BC (1982) Effect of pyridoxine supplementation on recurrent stone formers. Int J Clin Pharmacol Ther Toxicol 20:434–437
Murthy MSR, Talwar HS, Thind SK, Nath R (1982) Vitamin B6 deficiency as related to oxalate synthesising enzymes in growing rats. Ann Nutr Metab 26:201–208
Natelson S (1963) Microtechniques of clinical chemistry, 2nd edn. Thomas, Springfield
Ogawa Y, Yamaguchi K, Morozumi M (1990) Effects of magnesium salts in preventing oxalate urolithiasis in rats. J Urol 144:385–389
Prien EL, Gershoff SF (1974) MgO: pyridoxine therapy for recurrent calcium oxalate calculi. J Urol 112:509–512
Rattan V, Thind SK, Jethi RK, Sidhu H, Nath R (1993) Oxalate metabolism in magnesium-deficient rats. Magnes Res 6:125–131
Robertson WG, Peacock M, Marshall RW, Marshall DH, Nordin BEC (1976) Saturation-inhibition index as a measure of risk of calcium oxlate stone formation in the urinary tract. N Engl J Med 294:249–252
Sakhaee K, Nicar M, Hill K, Pak CYC (1983) Contrasting effects of potassium citrate and sodium citrate therapies on urinary chemistry and crystallization of stone forming salts. Kidney Int 24:348–352
Smith LH (1990) Idiopathic calcium oxalate urolithiasis Endocrinol Metab Clin North Am 19:937–947
Takasaki E (1972) The magnesium-calcium ratio in the concentrated urines of patients with calcium oxalate calculi. Invest Urol 10:147–150
Takasaki E (1975) Urinary magnesium and oxalic acid ecretion in patients with recurrent oxalate urolithiasis. Invest Urol 12:251–259
Tiselius HG (1982) An improved method for the routine biochemical evaluation of patients with recurrent calcium oxalate stone disease. Clin Chim Acta 122:409–418
Tiselius HG, Ahlstrand C, Larsson L (1980) Urine composition in patients with urolithiasis during treatment with MgO. Urol Res 8:197–200
Trinder P (1960) Calcium determination by precipitation. In: Wootton IDP (ed) Microanalysis in medical biochemistry, 4th edn. London, Churchill, p 176
Uribari J, Man S, Carroll JH (1989) The first kidney stone. Ann Intern Med 111:1006–1009
White JCD, Davies DJ (1963) The determination of citric acid in milk and milk sera. J Dairy Res 30:171–189
Will EJ, Bijovet OLM (1979) Primary hyperoxaluria, clinical and biochemical response to high dose pyridoxine therapy. Metab Clin Exp 28:542–547
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Rattan, V., Sidhu, H., Vaidyanathan, S. et al. Effect of combined supplementation of magnesium oxide and pyridoxine in calcium-oxalate stone formers. Urol. Res. 22, 161–165 (1994). https://doi.org/10.1007/BF00571844
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00571844